Although therapy with bevacizumab showed no efficacy in GC patients, both preclinical and clinical studies indicated that anti-VEGF therapy is effective in reducing ascitic cancerous exudates in GC and other tumors [4, 5]. This evidence concerns the gene VEGFA and gastric cancer.